ExPRESS miniature glaucoma shunt for intractable secondary glaucoma in superior vena cava syndrome - a case report
© The Author(s). 2016
Received: 12 March 2016
Accepted: 13 July 2016
Published: 26 July 2016
The aim of this study was to clarify the pathogenic mechanism and to evaluate an intervention for intractable secondary glaucoma in superior vena cava (SVC) syndrome.
A 66-year-old female with underlying hypertension, diabetes mellitus, ischaemic heart disease and end-stage renal disease complained of bilateral puffy eyelids for 3 months. Over three years, the patient experienced a progressive, marked face and neck swelling, which was accompanied by dyspnoea and nocturnal coughing. The patient has been under haemodialysis for the past 5 years; there were several occurrences of vascular access re-establishment for susceptibility to vascular thrombosis, and she was also diagnosed with SVC syndrome 2 years after haemodialysis. The patient’s best-corrected visual acuity (BCVA) was 20/60 in the right eye and 20/400 in the left eye. Pneumatic tonometry revealed a gradual increase in the intraocular pressure (IOP), even with the use of three types of anti-glaucoma agents. The ratio was 0.7 and bilaterally symmetric; optical coherence tomography indicated a thinning of the superior and inferior retina nerve fibre layers, and standard automated perimetry showed partial to generalized depression in both eyes.
Filtering surgery for the left eye was performed, but postoperatively, the IOP increased gradually over three months. The subsequent placement of the ExPRESS miniature glaucoma device p200 effectively lowered the IOP. Postoperatively, the IOP of the left eye remained under 20 mmHg without a further decrease in visual acuity, while the right eye, which was controlled with only medication, had an IOP of greater than 30 mmHg. Because this patient refused cardiovascular intervention, conventional trabeculectomy was used to redirect the aqueous humour to the subconjunctival space to form a bleb, but failed. Fortunately, the subsequent ExPRESS implant effectively facilitated aqueous outflow through the intrascleral space, resulting in the maintenance of a normal IOP at 6 months, postoperatively.
Sustained high IOP may occur after conventional filtration surgery for secondary glaucoma in SVC syndrome. To facilitate aqueous outflow, an ExPRESS glaucoma implant can be used to effectively control the IOP.
KeywordsSecondary glaucoma Superior vena cava syndrome Trabeculectomy Express
Even though episcleral vein occlusion has been used to increase the intraocular pressure (IOP) in an animal model [1, 2], there are only a few in vivo studies on the course and management of such cases. Causes of obstruction of venous drainage that affect the eyes include episcleral vein obstruction, orbital disease, cavernous sinus thrombosis, jugular vein occlusion and superior vena cava obstruction. In particular, for patients under chronic haemodialysis, it is not uncommon that superior vena cava (SVC) syndrome may develop due to venous stenosis [3, 4].
In SVC syndrome cases, there is an obstruction of blood flow through the superior vena cava; and dyspnoea, chest pain, face edema, neck and eyelid swelling and ocular hypertension can occur because of the impaired venous drainage of body fluid. Nevertheless, Yu et al. previously proposed a classification for SVC syndrome; according to this report, visual symptoms are rare, and if visual disturbance by ocular oedema is present, the disease is graded as being in a moderate stage .
The drainage of the aqueous humour into the venous system improves the balance of the intraocular pressure and visual function. A blockade of the venous drainage is one of the rare causes of glaucoma with elevated episcleral pressure in SVC syndrome and might not be noticed due to its subtle ocular manifestation, especially before and after venous drainage impairment has been resolved. Thus far, a few case reports on ocular manifestations in SVC syndrome exist, but few studies have reported treatment for the eyes with elevated episcleral vein pressure.
Therefore, the purpose of this retrospective study was to clarify the underlying pathogenic mechanism and to evaluate the effective interventions of secondary glaucoma in SVC syndrome. In addition, we will establish the efficacy and safety of surgical intervention for secondary glaucoma in SVC syndrome.
A general inspection revealed the orthotropic primary ocular position without proptosis. The eyelids were swollen without tenderness or local heat, and initially, the intraocular pressure was normal. There was moderate congestion of the conjunctiva in both eyes; the corneas were clear, and the anterior chambers were deep and quiet. In 2013, two years after SVC syndrome was diagnosed, pneumatic tonometry revealed bilateral high IOP (22 mmHg OD, 23 mmHg OS) compared to a prior visit. Then, the IOP increased progressively to 30 mmHg, even with the combined use of brimonidine, dorzolamide and latanoprost, which was aimed at controlling IOP. At that time, the patient’s best-corrected visual acuity (BCVA) was 20/60 in the right eye and 20/400 in the left eye. Gonioscopy demonstrated wide-open angles in both eyes without peripheral anterior synechiae or neovascularization of the angle. Upon fundus examination, the cup-to-disk ratio was found to have increased to 0.7 in both eyes after one and half years of treatment with an anti-glaucoma agent. Optical coherence tomography showed the superior and inferior thinning of the retinal nerve fibre layer (RNFL) in both eyes, which was worse on the left side. Specifically, the patient had an average RNFL of 65.57 μm in the right eye and 47.51 μm in the left eye. Standard automated perimetry showed a three-fourths quadrant depression in the right eye and more generalized depression in the left eye; the mean deviations were -17.57 and -27.07, respectively.
During the management of intractable secondary glaucoma, we reviewed the patient’s past medical history and image data and found that the patient was susceptible to vascular thrombosis and stenosis, as evidenced by the high venous pressure observed during haemodialysis, and while creating the vascular shunt, repeated angioplasty and thrombectomy for venous outlet thrombosis were required. There were multiple attempts at creating vascular accesses during the initial 2 years. First, a right neck Hickman catheter was inserted for temporary haemodialysis access, after which a second was placed in her right arm, but failed within a short time. Third, an arteriovenous fistula (AVF) was created in the left arm with a radial arterial-cephalic vein anastomosis, which failed in three years and was replaced by an arteriovenous graft (AVG) between the brachial artery and the axillary vein in the left arm after 6 months. The patient had been under haemodialysis via AVG since then, but encountered acute occlusion once and received a balloon percutaneous transluminal angioplasty (PTA). In 2011, the patient was admitted once for SVC syndrome after an unsuccessful attempt to place a Hickman catheter from the right and left internal jugular vein to bypass the complete obstruction of the right subclavian vein and right brachiocephalic vein. PTA was performed unsuccessfully, despite the spontaneous resolution of oedema on the left side of the face. However, the patient presented with intermittent recurrence and indolent face and neck oedema afterwards. Over the next 3 years, marked SVCS, accompanied by uncontrollable IOP, led to irreversible glaucomatous optic neuropathy. Although femoral double lumen creation and venous bypass construction were suggested as alternative haemodialysis access routes, along with the ligation of the previous AVF in the left arm, the patient refused any cardiovascular surgical options.
SVC syndrome due to the obstruction of blood flow occurs most frequently in intrathoracic malignancy, while SVC syndrome due to intravascular devices, such as in haemodialysis, is rare . Although SVC syndrome is usually not life threatening and there is a lack of randomized clinical trials, Yu et al. previously proposed a classification for SVC syndrome; however, there is no consensus on the ocular manifestation and management . Our case, which was graded as 2 according to Yu’s classification, demonstrated moderate haemodynamic symptoms, such as oedema of the head, including the eyelids and neck, without respiratory and neurologic signs. Although the timepoint of the onset of secondary glaucoma is unclear, we eventually observed irreversible visual deterioration.
As this patient would not accept suggestions for further interventions for the unmanageable venous occlusion, the IOP increase persisted, even with medication. Similar to results reported in a review for the management of elevated episcleral pressure , conventional antiglaucoma agents were not beneficial for our patient, who had unchanged SVC syndrome. Furthermore, after the first surgical intervention with trabeculectomy, the patient’s IOP gradually increased after 3 months. ExPRESS was performed secondarily, and the IOP was stabilized for 6 months, without postoperative complications.
Glaucoma filtration surgery has been a priority surgical intervention in primary glaucoma for decades. Trabeculectomy redirects the aqueous humour to the subconjunctival space to gradually form a bleb. However, this has a limited effect in patients with secondary glaucoma in SVC syndrome with venous drainage impairment. However, our results showed that after primary filtration surgery failed, the ExPRESS implant effectively facilitated aqueous outflow through the intrascleral space, thereby resulting in a normal IOP. In contrast, the IOP of the other eye, for which the patient refused any further intervention, remained high, despite treatment with medication.
Secondary glaucoma with elevated episcleral pressure in SVC syndrome needs attention because the early ocular symptoms may be subtle. Although no randomized clinical trials for the treatment of elevated episcleral venous pressure exist, the ExPRESS miniature glaucoma implant may be an option for IOP control. Optimal management can thus prevent irreversible vision deterioration.
AVF, arteriovenous fistula; AVG, arteriovenous graft; BCVA, best-corrected visual acuity; CTA, computed tomography angiography; IOP, intraocular pressure; OD, right eye; OS, left eye; PTA, percutaneous transluminal angioplasty; RNFL, retinal nerve fibre layer; SVC, superior vena cava
The authors do not have any acknowledgements regarding this case report.
No funding is declared for this report.
Availability of data and materials
Data supporting our findings can be found at the following link: https://dx.doi.org/https://doi.org/10.6084/m9.figshare.3380131.v1.
LH Chuang and YJ Ho made equal contributions to the study conception and design, and both were involved in drafting the manuscript. CH Yeh and CC Lai both made contributions to data acquisition, analysis and interpretation. Jerry CC Huang revised the manuscript for important intellectual content. All of the authors read and approved the final manuscript.
YJ Ho and CC Lai are MDs in the Department of Ophthalmology, Chang Gung Memorial Hospital, Linkou, Taiwan. Jerry CC Huang and LH Chuang are MDs in the Department of Ophthalmology, Chang Gung Memorial Hospital, Keelung, Taiwan. CH Yeh is an MD and PhD in the Department of Thoracic and Cardiovascular Surgery, Chang Gung Memorial Hospital, Keelung, Taiwan.
The authors declare that they have no competing interests.
Consent to publish
Written informed consent was obtained from the patient for the publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
Ethics approval and consent to participate
This study protocol was approved by the Human Research Ethics Committee at Chang Gung Memorial Hospital in Taiwan (No. 104-3815B) and adhered to the tenets of the Declaration of Helsinki. Written informed consent was obtained from the patient for participating in this study.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Danias J1, Shen F, Kavalarakis M, Chen B, Goldblum D, Lee K, Zamora MF, Su Y, Brodie SE, Podos SM, Mittag T. Characterization of retinal damage in the episcleralvein cauterization rat glaucoma model. Exp Eye Res. 2006;82:219–28.View ArticlePubMedGoogle Scholar
- Ruiz-Ederra J, Verkman AS. Mouse model of sustained elevation in intraocular pressure produced by episcleral vein occlusion. Exp Eye Res. 2006;82:879–84.View ArticlePubMedGoogle Scholar
- Cleper R, Goldenberg-Cohen N, LioraKornreich IK, Davidovits M. Neurologic and ophthalmologic complications of vascular access in a hemodialysis patient. Pediatr Nephrol. 2007;22:1377–82.View ArticlePubMedGoogle Scholar
- Choni R, Efrat B-S, Rachel B-C, Sofia F, Yaacov F. Complications of central venous stenosis due to permanent central venous catheters in children on hemodialysis. Pediatr Nephrol. 2014;29:2235–9.View ArticleGoogle Scholar
- Yu JB1, Wilson LD, Detterbeck FC. Superior vena cava syndrome--a proposed classification system and algorithm for management. J Thorac Oncol. 2008;3:811–4.View ArticlePubMedGoogle Scholar
- Sit AJ, McLaren JW. Measurement of episcleral venous pressure. Exp Eye Res. 2011;93:291–8.View ArticlePubMedGoogle Scholar